Both approved PNH complement inhibitors cleared NICE's standard £20,000 to 30,000 per QALY bar, leaving the EVH-dominant population as the real differentiation opportunity.

Ravulizumab (Ultomiris, AstraZeneca) is NHS England's commissioned PNH standard of care via NICE TA698, a standard Technology Appraisal published 19 May 2021, dosed IV every eight weeks at a UK list price near £335,000 a year with PAS, and administered at roughly 20 NHS PNH specialist centres. Switching friction in stable patients is high, so a new entrant must show an EVH-specific or oral advantage to earn consideration. The one meaningful crack in ravulizumab's position is extravascular haemolysis, persistent anaemia despite adequate C5 blockade. Leeds National PNH Registry data puts the EVH-dominant, transfusion-burdened cohort at roughly 200-250 of the 1,000 UK patients on complement inhibition, rising toward 400-500 under a broader residual-anaemia definition.

Despite PNH's ultra-rare prevalence, NICE has routed every approved complement inhibitor through the standard Technology Appraisal process rather than the softer Highly Specialised Technology pathway reserved for conditions affecting 500 or fewer patients a year in England. Ravulizumab cleared NICE as TA698 on the standard route, and iptacopan (Fabhalta, Novartis), the first oral Factor B inhibitor, has since cleared as TA1000, NICE's 1,000th published appraisal, with a final positive recommendation now in place. That precedent is the clearest available signal for a pre-launch asset: expect NICE's ordinary £20,000-30,000 per QALY bar, not the ultra-rare threshold, regardless of how narrowly the indication is framed.

NICE treats PNH as ordinary, not ultra-rare, regardless of how the indication is framed.

Five questions this report answers:

Q1 - Why has NICE routed every approved PNH agent through standard appraisal rather than the ultra-rare pathway?

Q2 - How large is the UK's EVH-dominant PNH population before MHRA approval?

Q3 - What PAS discount and regulatory sequence clear NICE's cost-effectiveness bar on MHRA's timeline?

Q4 - What deliverable formats come with a commissioned UK launch readiness assessment?

Q5 - What does a pre-launch PNH asset need to prove to succeed in the UK market?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #NICE #UKMarketAccess #LaunchReadiness #RareDisease

Live report page:  https://axlrx.ai/pnh/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/